Cargando…
Genome-Wide Association Study of Ustekinumab Response in Psoriasis
Heterogeneous genetic and environmental factors contribute to the psoriasis phenotype, resulting in a wide range of patient response to targeted therapies. Here, we investigate genetic factors associated with response to the IL-12/23 inhibitor ustekinumab in psoriasis. To date, only HLA-C*06:02 has...
Autores principales: | Connell, William T., Hong, Julie, Liao, Wilson |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830831/ https://www.ncbi.nlm.nih.gov/pubmed/35154085 http://dx.doi.org/10.3389/fimmu.2021.815121 |
Ejemplares similares
-
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019) -
Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020) -
Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011) -
Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab
por: Campbell, Kim, et al.
Publicado: (2023) -
Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)